p95HER2 and Breast Cancer

被引：183

作者：

Arribas, Joaquin ^{[1
,2
,3
]}

Baselga, Jose ^{[1
]}

Pedersen, Kim ^{[1
]}

Parra-Palau, Josep Lluis ^{[1
]}

机构：

[1] Autonomous Univ Barcelona, VHIO, Bellaterra, Spain

[2] Autonomous Univ Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain

[3] ICREA, Barcelona, Spain

来源：

CANCER RESEARCH | 2011年 / 71卷 / 05期

关键词：

CARBOXY-TERMINAL FRAGMENT; GROWTH-FACTOR RECEPTOR; EXTRACELLULAR DOMAIN; TRASTUZUMAB RESISTANCE; ESTROGEN-RECEPTOR; KINASE DOMAIN; PI3K PATHWAY; HER2; ACTIVATION; MUTATIONS;

D O I：

10.1158/0008-5472.CAN-10-3795

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A subtype of HER2-positive tumors with distinct biological and clinical features expresses a series of carboxyterminal fragments collectively known as p95HER2. One of these fragments, named 100- to 115-kDa p95HER2 or 611-CTF, is hyperactive because of its ability to form homodimers maintained by intermolecular disulfide bonds. Despite lacking the majority of the extracellular domain, this HER2 fragment drives breast cancer progression in vivo. The recent availability of specific anti-p95 antibodies has confirmed previous results indicating that the expression of p95HER2 is predictive of poor prognosis and correlates with resistance to the treatment with trastuzumab, a therapeutic antibody directed against the extracellular domain of HER2. Cancer Res; 71(5); 1515-9. (C)2011 AACR.

引用

收藏

页码：1515 / 1519

页数：5

相关论文

共 29 条

[1] Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation [J].

Anido, Judit ;

Scaltriti, Maurizio ;

Bech Serra, Joan Josep ;

Santiago Josefat, Belen ;

Rojo Todo, Federico ;

Baselga, Jose ;

Arribas, Joaquin .

EMBO JOURNAL, 2006, 25 (13) :3234-3244

[2] HER2 Fragmentation and Breast Cancer Stratification [J].

Arribas, Joaquin ;

Lluis Parra-Palau, Josep ;

Pedersen, Kim .

CLINICAL CANCER RESEARCH, 2010, 16 (16) :4071-4073

[3] Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 [J].

Baselga, Jose ;

Swain, Sandra M. .

NATURE REVIEWS CANCER, 2009, 9 (07) :463-475

[4] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[5] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J].

Cho, HS ;

Mason, K ;

Ramyar, KX ;

Stanley, AM ;

Gabelli, SB ;

Denney, DW ;

Leahy, DJ .

NATURE, 2003, 421 (6924) :756-760

[6]

Christianson TA, 1998, CANCER RES, V58, P5123

[7] Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235 [J].

Eichhorn, Pieter J. A. ;

Gili, Magui ;

Scaltriti, Maurizio ;

Serra, Violeta ;

Guzman, Marta ;

Nijkamp, Wouter ;

Beijersbergen, Roderick L. ;

Valero, Vanesa ;

Seoane, Joan ;

Bernards, Rene ;

Baselga, Jose .

CANCER RESEARCH, 2008, 68 (22) :9221-9230

[8] HER2 Carboxyl-terminal Fragments Regulate Cell Migration and Cortactin Phosphorylation [J].

Garcia-Castillo, Jesus ;

Pedersen, Kim ;

Angelini, Pier-Davide ;

Josep Bech-Serra, Joan ;

Colome, Nuria ;

Paul Cunningham, Matthew ;

Lluis Parra-Palau, Josep ;

Canals, Francesc ;

Baselga, Jose ;

Arribas, Joaquin .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (37) :25302-25313

[9] Selective estrogen receptor modulation: Concept and consequences in cancer [J].

Jordan, VC .

CANCER CELL, 2004, 5 (03) :207-213

[10] Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas [J].

Lal, P ;

Tan, LK ;

Chen, BY .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (04) :541-546